PHAT Phathom Corp Gross Profit Margin

PHAT (Phathom Pharma) - company brandmark

Rapid sales growth of Voquezna for the treatment of esophagitis is currently driving revenue for Phathom Pharmaceuticals (PHAT), which validates the business's gross margins. This trend is supported by the blockbuster's expansion and the broadening of insurance coverage in the US. Leadership in GI therapy guarantees stable demand and high-quality FCF. The value of 80.70 serves as the base parameter, helping investors more accurately calculate the asset's intrinsic value.

phathompharma.com (PHAT): Return on Gross Profit from 07/04/2022 to 11/20/2026

Financial and market metric breakdowns for Phathom Pharmaceuticals (PHAT)

- stock price and consensus target price:
Fundamental valuation:Phathom Pharmaceuticals
Product sample of Phathom

Gross margin is calculated as the difference between revenue and cost of goods sold, measuring direct production efficiency and the business's ability to generate profit from each unit of product. For Phathom Pharmaceuticals (PHAT), the growth of this metric on GURU.Markets confirms the scaling of sales for its esophagitis drug and a transition toward operational stability, which is reflected in the rising gross profit margin.